63671-68-1

Usage

Derivative of phenol

Contains a pyridylmethylamino group attached to the phenol ring

Potential biological activities

Anti-tumor agent, ability to inhibit the proliferation of cancer cells

Potential use in

Fluorescence imaging, coordination chemistry as a ligand

Versatile molecule

Applicable in various fields of research and technology

Upstream product

• 90-02-8 salicylaldehyde 
• 3731-51-9 2-(Aminomethyl)pyridine 
• 137129-33-0 2-((E)-((pyridin-2-yl)methylimino)methyl)phenol 
• 1121-60-4 pyridine-2-carbaldehyde 
• 932-30-9 2-Hydroxybenzylamine 
• 137129-33-0 2-((pyridin-2-ylmethylimino)methyl)phenol 

Downstream Products

• 170659-81-1 2-[[bis(2-pyridinomethyl)amino]methyl]-6-[[[(2-hydroxyphenyl)methyl](2-pyridinylmethyl)amino]methyl]-4-methylphenol 
• 287183-56-6 N-(2-hydroxybenzyl)-N-(2-pyridylmethyl)-[(3-chloro)(2-hydroxy)]propylamine 
• 481050-72-0 N-2-pyridylmethyl-N-2-hydroxybenzyl-3-aminomethylindole 

Relevant academic research and scientific papers

Synthesis, characterization and DFT studies of a new unsymmetrical dinuclear Vanadium(IV) complex with a bipodal N2O-donor ligand

A new dinuclear vanadium(IV) complex [(VO)2(μ-HBPA)2(μ-SO4)].4.75H2O was synthesized by the reaction between a bipodal N2O-donor ligand N-(2-hydroxybenzyl)-N-(pyridin-2-ylmethyl)amine (HBPA) and vanad

Binucleating Hydrazonic Ligands and Their μ-Hydroxodicopper(II) Complexes as Promising Structural Motifs for Enhanced Antitumor Activity

Very few inorganic antineoplastic drugs have entered the clinic in the last decades, mainly because of toxicity issues. Because copper is an essential trace element of ubiquitous occurrence, decreased side effects could be expected in comparison with the widely used platinum anticancer compounds. In the present work, two novel hydrazonic binucleating ligands and their μ-hydroxo dicopper(II) complexes were prepared and fully characterized. They differ by the nature of the aromatic group present in their aroylhydrazone moieties: while H3L1 and its complex, 1, possess a thiophene ring, H3L2 and 2 contain the more polar furan heterocycle. X-ray diffraction indicates that both coordination compounds are very similar in structural terms and generate dimeric arrangements in the solid state. Positive-ion electrospray ionization mass spectrometry analyses confirmed that the main species present in a 10% dimethyl sulfoxide (DMSO)/water solution should be [Cu2(HL)(OH)]+ and the DMSO-substituted derivative [Cu2(L)(DMSO)]+. Scattering techniques [dynamic light scattering (DLS) and small-angle X-ray scattering] suggest that the complexes and their free ligands interact with bovine serum albumin (BSA) in a reversible manner. The binding constants to BSA were determined for the complexes through fluorescence spectroscopy. Moreover, to gain insight into the mechanism of action of the compounds, calf thymus DNA binding studies by UV-visible and DLS measurements using plasmid pBR322 DNA were also performed. For the complexes, DLS data seem to point to the occurrence of DNA cleavage to Form III (linear). Both ligands and their dicopper(II) complexes display potent antiproliferative activity in a panel of four cancer cell lines, occasionally even in the submicromolar range, with the complexes being more potent than the free ligands. Our data on cellular models correlate quite well with the DNA interaction experiments. The results presented herein show that aroylhydrazone-derived binucleating ligands, as well as their dinuclear μ-hydroxodicopper(II) complexes, may represent a promising structural starting point for the development of a new generation of highly active potential antitumor agents.

Turn-on selective fluorescent probe for trivalent cations

A novel fluorescent sensor 1 (1 = 10-(2-(((pyridin-2-yl)methylamino)methyl) phenol)methyl-anthracene) for trivalent cations has been synthesized and characterized. Both UV-vis and fluorescence spectroscopic studies demonstrated that the new receptor 1 was

COMPOUNDS FOR PREVENTING MIGRATION OF CANCER CELLS

The present invention relates to a composition for use in preventing migration of cancer cells in a subject known or suspected to suffer from cancer, the composition comprising at least one metal complex having the structure (I), formula (I), wherein M is a metal, preferably selected from the group consisting of copper, iron, manganese and zinc, X is Xa or Xb, wherein Xa is selected from the group consisting of O, S and -N(R1)-, wherein R1 is H or alkyl, and wherein Xb is a group forming a coordinate covalent bond to a second metal M', preferably a group O, S or -N(R1)-, wherein M' is preferably selected from the group consisting of copper, iron, manganese and zinc, and wherein M' and M may be the same or different and are preferably the same, Z1 and Z2, are independently of each other a, substituted or unsubstituted, -Aryl-O-, -Aryl-N- or heteroaryl group, Y is Ya or Yb, wherein Ya is selected from the group consisting of H, alkyl, -OH, -SH, halogen, and -NR3R4, wherein R3 and R4, are independently of each other selected from H and alkyl, preferably R3 and R4 are both H, and wherein Yb is a group forming a coordinate covalent bond to M or M', preferably Yb is a group O, S or -N(RYb1RYb2), wherein RYb1 and RYb1, are, independently of each other, H or alkyl, preferably H, and wherein n and m are integers, which are independently of each other, 0 or 1, Y2 is water or a halogen, and wherein Y3 is water or a halogen. The present invention further relates to a combined preparation comprising the aforesaid composition as well as to an in vitro method, for determining whether cancer cells are susceptible to immobilizing by the aforesaid compound.

Copper(II) Pyridyl Aminophenolates: Hypoxia-Selective, Nucleus-Targeting Cytotoxins, and Magnetic Resonance Probes

Targeting the low-oxygen (hypoxic) environments found in many tumours by using redox-active metal complexes is a strategy that can enhance efficacy and reduce the side effects of chemotherapies. We have developed a series of CuII complexes with

Trinuclear platinum coordination compoundbased on tri-homoazine, preparation method and application thereof

The invention discloses a tri-homoazine-based trinuclear platinum coordination compound, a preparation method and application thereof, wherein the structural formula of the tri-homoazine-based trinuclear platinum coordination compound is shown in the spec

Activity-Based Sensing of Ascorbate by Using Copper-Mediated Oxidative Bond Cleavage

Ascorbate is an important biological reductant and enzyme cofactor. Although direct detection through ascorbate-mediated reduction is possible, this approach suffers from poor selectivity due to the wide range of cellular reducing agents. To overcome this limitation, we leverage reduction potential of ascorbate to mediate a copper-mediated oxidative bond cleavage of ether-caged fluorophores. The copper(II) complexes supported by a {bis(2-pyridylmethyl)}benzylamine or a {bis(2-pyridylmethyl)}(2-methoxybenzyl)amine ligand were identified as an ascorbate responsive unit and their reaction with ascorbate yields a copper-based oxidant that enables rapid benzylic oxidation and the release of an ether-caged dye (coumarin or fluorescein). The copper-mediated bond cleavage is specific to ascorbate and the trigger can be readily derivatized for tuning photophysical properties of the probes. The probes were successfully applied for the fluorometric detection of ascorbate in commercial food samples, human plasma, and serum, and within live cells by using confocal microscopy and flow cytometry.

Homodinuclear [Fe(III)?Fe(III)] and [Zn(II)?Zn(II)] complexes of a binucleating [N4O3] symmetrical ligand with purple acid phosphatase (PAP) and zinc phosphoesterase like activity

The homodinuclear [Fe(III)–Fe(III)] (2) and [Zn(II)–Zn(II)] (3) complexes of binucleating [N4O3] symmetrical ligand (1) of the formulation, H3L (L = 2,6-bis{[(2-hydroxybenzyl)(2-pyridylmethyl)amino]methyl}-4-t-butylphenolate), display purple acid phosphatase (PAP) and zinc phosphoesterase like activity. For the two complexes, the spectrophotometric titration and the ESI-MS studies supported the existence of an equilibrium between a triaquated species, {L[(H2O)FeIII(μ-H2O)FeIII(H2O)]}3+ (2A) and {L[(H2O)ZnII(μ-H2O)ZnII(H2O)]}+ (3A), a diaquated and monohydroxo species, {L[(H2O)FeIII(μ-H2O)FeIII(OH)]}2+ (2B) and {L[(H2O)ZnII(μ-H2O)ZnII(OH)]} (3B), a monoaquated and dihydroxo species, {L[(H2O)FeIII(μ-OH)FeIII(OH)]}+ (2C) and {L[(H2O)ZnII(μ-OH)ZnII(OH)]}? (3C), and a trihydroxo species, {L[(HO)FeIII(μ-OH)FeIII(OH)]} (2D) and {L[(HO)ZnII(μ-OH)ZnII(OH)]}2? (3D), depending upon the pH of the solution. Of these, the active species namely, a monoaquated and dihydroxo species, {L[(H2O)FeIII(μ-OH)FeIII(OH)]}+ (2C) and {L[(H2O)ZnII(μ-OH)ZnII(OH)]}? (3C), hydrolyzed an activated substrate bis(2,4-dinitrophenyl)phosphate at the pH range of 5.5–10.5, displaying Michealis–Menton kinetics. Significantly enough, the catalyst-substrate adduct of the type {L[FeIII(μ-OH)(μ-RPO4)FeIII]} (2F) has been detected by ESI-MS for the dinuclear [Fe(III)–Fe(III)] complex (2).

Preparation method and application of Asymmetric N-O ligand and Ti, Zr and Hf complex

The invention discloses a preparation method and application of asymmetric N-O ligand and Ti, Zr and Hf complex. The preparation method of the complex comprises the following steps: preparing asymmetric N-O ligand from substituted salicylaldehyde with 2-(

Novel A-PAP Compounds, Agent Selecting Trivalent Cation Using The Same, Detecting Method And Detecting Device Thereof

The present invention relates to a novel 10-(2-(((pyridin-2-yl)methyl amino) methyl)phenol)methylanthracene (A-PAP) compound, a detecting agent comprising the compound having specific selectivity to trivalent metal ion (M3+), and a detecting method and a